# Maxwellia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maxwellia

- Industry: Healthcare
- Headquarters: Cheshire, UK
- Website: www.maxwellia.com
- Total disclosed funding: $1M
- Latest round: Seed (Mar 23, 2018)
- Investors on record: 1

## About

Maxwellia Ltd is an innovative consumer healthcare company dedicated to enhancing access to medicines by transforming prescription medications into over-the-counter products, catering to various healthcare needs.Established in 2013 in Cheshire, UK, Maxwellia Ltd specializes in consumer healthcare, converting prescription products into OTC offerings. The company has completed two deals, with the most recent deal on March 26, 2021, where they raised GBP 3.23 million led by Praetura Ventures. The current CEO is Anna Maxwell, who has a history of founding and leading ventures in the healthcare sector.Maxwellia offers a range of OTC products aimed at improving self-management of health, including Ultravana® for period pain relief, Evana® for heavy menstrual bleeding, Lovima® as a daily contraceptive pill, and LoviOne® for emergency contraception. These products are designed to meet specific healthcare needs, enabling individuals, particularly women, to manage their health without prescriptions. Their products are available in pharmacies and high street retailers across the UK and select European markets.Maxwellia generates revenue through direct distribution of its OTC products to consumers via retail outlets, partnering with wholesalers to ensure product availability. Their pricing strategy for key products like Ultravana®, Evana®, Lovima®, and LoviOne® is competitive, aiming to make essential healthcare solutions affordable while maintaining quality. This transactional framework supports a consistent flow of product delivery and contributes to their market presence.Following their GBP 3.23 million funding round on March 26, 2021, led by Praetura Ventures, Maxwellia Ltd plans to utilize the funds to scale up manufacturing and rollout of its drugs after receiving MHRA approval, invest in marketing, and expand their team. The company aims to introduce new products and expand into additional markets, enhancing their footprint in the healthcare sector.

## Funding rounds

- Seed, Mar 23, 2018, $1M — Catapult

## Investors

- Catapult — Seed